Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aerie Pharmaceuticals
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

1. 18 years of age or older.

2. Ocular hypertension or open-angle glaucoma in both eyes.

3. Unmedicated intraocular pressure > 17 mmHg in one or both eyes and < 30 mmHg in both eyes.

4. Corrected visual acuity in each eye equivalent to 20/200 or better.

5. Able and willing to give signed informed consent and follow study instructions.

Exclusion Criteria:

1. Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, narrow angles.

2. Intraocular pressure ≥ 30 mmHg.

3. Use of ocular medications within 30 days.

4. Known hypersensitivity to any component of the test formulations or to medications used routinely during a clinical eye examination.

5. Previous eye surgery (other than cataract).

6. Ocular trauma within 6 months.

7. Clinically significant ocular disease that might interfere with the study.

8. Central corneal thickness greater than 620 µm.